SOCS2 is part of a highly prognostic 4-gene signature in AML and promotes disease aggressiveness

Abstract excerpt

Acute myeloid leukemia (AML) is a heterogeneous disease with respect to its genetic and molecular basis and to patients´ outcome. Clinical, cytogenetic, and mutational data are used to classify patients into risk groups with different survival, however, within-group heterogeneity is still an issue. Here, we used a robust likelihood-based survival modeling approach and publicly available gene expression data to...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acute Myeloid Leukemia Research
• Share to Cytokine Signaling Pathways and Interactions
• Share to Myeloproliferative Neoplasms: Diagnosis and Treatment